Latest stories on DRMA
Dermata Therapeutics (DRMA) Launches Clinical Trial for Once-Weekly Acne Treatment
GuruFocus58 · neutralproduct/pr
Dermata Therapeutics, Inc. (DRMA) files 8-K
SEC 8-K50 · neutralgeneral
Dermata initiates acne clinical trial of second Tome skincare product
The Fly58 · neutralproduct/pr
Dermata Advances Second Tome Skincare Product Toward Expected 2027 Launch with Initiation of Acne Clinical Trial
StockTitan61 · neutralproduct/pr
DRMA jumps as Tome cosmetic study reports 71% seeing overall skin improvement after one treatment
October 15, 2026
MarketChameleon74 · bullishproduct/pr
Dermata announces results from study evaluating Tome Foundational Treatment
The Fly56 · neutralproduct/pr
Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
StockTitan64 · neutralproduct/pr
Dermata Therapeutics registers to sell 6.92M shares of common stock for holders
The Fly22 · bearishgeneral
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
StockTitan63 · neutralproduct/pr
Dermata Therapeutics announces Tome Foundational Treatment open to preorders
The Fly56 · neutralproduct/pr
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
StockTitan63 · neutralproduct/pr
Dermata Therapeutics Announces Private Placement to Fund DTC Pivot
TipRanks24 · bearishgeneral
Dermata Therapeutics announces $3.4M private placement
Seeking Alpha24 · bearishgeneral
Dermata Therapeutics prices 2.29M shares at $1.46 in private placement
The Fly28 · bearishgeneral
Dermata Therapeutics, Inc. (DRMAW) files 8-K
SEC 8-K50 · neutralgeneral
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
StockTitan28 · bearishgeneral
Dermata Sets Sights on August Launch of Tome™ as Strategic Pivot Drives Commercial Focus
August 12, 2026
MarketChameleon58 · neutralproduct/pr
Dermata Therapeutics GAAP EPS of -$0.74 misses by $0.19
Seeking Alpha34 · bearishearnings
Dermata Therapeutics, Inc. (DRMAW) files 8-K
SEC 8-K50 · neutralgeneral
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
StockTitan56 · neutralearnings
Dermata Therapeutics, Inc. (DRMAW) files 8-K
SEC 8-K50 · neutralgeneral
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
StockTitan63 · neutralproduct/pr
Dermata Therapeutics GAAP EPS of -$0.48 beats by $0.05
Seeking Alpha56 · neutralearnings
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
Morningstar56 · neutralearnings